ArticleThe Journal of pediatrics2014
Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants.
Article in The Journal of pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.The Cochrane database of systematic reviews · 2021Pooled it
- Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.The Cochrane database of systematic reviews · 2021Pooled it
- Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.The Cochrane database of systematic reviews · 2017Pooled it
- Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.The Cochrane database of systematic reviews · 2017Pooled it
- Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants.JAMA network open · 2022Trial
- Bronchopulmonary dysplasia: how can we improve its outcomes?Korean journal of pediatrics · 2019Article
- Circulating blood cellular glucose transporters - Surrogate biomarkers for neonatal hypoxic-ischemic encephalopathy assessed by novel scoring systems.Molecular genetics and metabolism · 2019Article
- Prevention and management of bronchopulmonary dysplasia: Lessons learned from the neonatal research network.Seminars in perinatology · 2016Review
- Respiratory management of extremely low birth weight infants: survey of neonatal specialists.World journal of pediatrics : WJP · 2016Article
- Birth Prevalence of Cerebral Palsy: A Population-Based Study.Pediatrics · 2016Article
- The Ages and Stages Questionnaire and Neurodevelopmental Impairment in Two-Year-Old Preterm-Born Children.PloS one · 2015Article
- Evidence for adverse effect of perinatal glucocorticoid use on the developing brain.Korean journal of pediatrics · 2014Review
- Hypertrophic intraventricular flow obstruction after very-low-dose dexamethasone (Minidex) in preterm infants: case presentation and review of the literature.Journal of perinatology : official journal of the California Perinatal Association · 2014Review
- Stopping the swinging pendulum of postnatal corticosteroid use.The Journal of pediatrics · 2014Article
Corrections and comments
- Commented on by
Authors and funding
25 authors at 19 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the incidence of death or neurodevelopmental impairment (NDI) at 18-22 months corrected age in subjects enrolled in a trial of early dexamethasone treatment to prevent death or chronic lung disease in extremely low birth weight infants. STUDY
designEvaluation of infants at 18-22 months corrected age included anthropomorphic measurements, a standard neurological examination, and the Bayley Scales of Infant Development-II, including the Mental Developmental Index and the Psychomotor Developmental Index. NDI was defined as moderate or severe cerebral palsy, Mental Developmental Index or Psychomotor Developmental Index <70, blindness, or hearing impairment.
resultsDeath or NDI at 18-22 months corrected age was similar in the dexamethasone and placebo groups (65% vs 66%, P = .99 among those with known outcome). The proportion of survivors with NDI was also similar, as were mean values for weight, length, and head circumference and the proportion of infants with poor growth (50% vs 41%, P = .42 for weight less than 10th percentile); 49% of infants in the placebo group received treatment with corticosteroid compared with 32% in the dexamethasone group (P = .02).
conclusionThe risk of death or NDI and rate of poor growth were high but similar in the dexamethasone and placebo groups. The lack of a discernible effect of early dexamethasone on neurodevelopmental outcome may be due to frequent clinical corticosteroid use in the placebo group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.